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Abstract
Effect modification occurs while the effect of the treatment is not homogeneous across
the different strata of patient characteristics. When the effect of treatment may vary
from individual to individual, precision medicine can be improved by identifying patient
covariates to estimate the size and direction of the effect at the individual level.
However, this task is statistically challenging and typically requires large amounts
of data. Investigators may be interested in using the individual patient data (IPD)
from multiple studies to estimate these treatment effect models. Our data arise
from a systematic review of observational studies contrasting different treatments
for multidrug-resistant tuberculosis (MDR-TB), where multiple antimicrobial agents
are taken concurrently to cure the infection. We propose a marginal structural model
(MSM) for effect modification by different patient characteristics and co-medications
in a meta-analysis of observational IPD. We develop, evaluate, and apply a targeted
maximum likelihood estimator (TMLE) for the doubly robust estimation of the
parameters of the proposed MSM in this context. In particular, we allow for differential
availability of treatments across studies, measured confounding within and across
studies, and random effects by study.
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Multidrug-resistant tuberculosis (MDR-TB), a form of tuberculosis (TB) with
high mortality, is caused by bacteria resistant to at least the two most
effective anti-TB drugs, isoniazid and rifampicin. According to the World Health
Organization (WHO) (2020), a global total of 206 030 patients with MDR-TB or
rifampicin-resistant (RR)-TB were detected and notified of their infection in 2019,
a 10% increase compared to cases in 2018. However, the latest data reported to
WHO show a treatment success rate for MDR/RR-TB of 57% globally.1 Treating
MDR-TB is challenging as a result of the heterogeneity of patients’ characteristics
(age, sex, HIV or other comorbidities), disease characteristics (extent and prior
treatment), mycobacteria itself (different patterns of additional resistance) and
characteristics of drugs (more toxicity and less effect of second-line drugs).2,3
Patients are typically prescribed a combination of four or more antimicrobial
agents depending on the therapeutic phase and drug resistance pattern, if known.4
In addition, the effect of a treatment regimen may vary by an individual’s
characteristics and the specific combination of medications. When the effect
and drug resistance pattern may vary from individual to individual, precision
medicine can be improved by identifying patient covariates to estimate the size
and direction of the effect at the individual level. In other words, identifying effect
modifiers and assessing effect modification between different patient subgroups
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should be considered. However, this task is statistically challenging and typically
requires large amounts of data so that treatment effects may be well-estimated for
different combinations of covariate values. One may impose a working model in
order to smooth (or summarize) the covariate-specific effects rather than estimate
a separate effect for each possible combination of patient covariates.5–7 When
working with observational data one must also adjust for all potential confounders
of the treatment-outcome relationship, which can be accomplished via propensity
scores and/or outcome regression modeling.8 One way to model effect modification
in a simple binary treatment setting is through a marginal structural model
(MSM) for the conditional average treatment effect (CATE).7,9 This model may
be interpreted as the relationship between covariates and the expected treatment
effect where the treatment effect is defined through a contrast of counterfactual
outcomes. In non-meta-analytical settings, doubly robust estimators have been
proposed for the estimation of a parametric MSM for the CATE7 as well as for
nonparametric CATE models.10
Due to the large data requirements for estimating effects across patient
subgroups, investigators may be interested in using individual participant data
(IPD) from multiple studies to fit these treatment effect models. In our study, the
data were extracted from 31 observational studies11 which contrasted different
treatment regimens for patients with MDR-TB, where multiple antimicrobial
agents are taken concurrently by a patient over a long period. Our objective is to
perform an IPD meta-analysis12 to investigate the impact of different patient and
treatment characteristics on the average treatment effect (ATE) of 14 anti-TB
medications.
In this project, we propose and evaluate a targeted maximum likelihood
estimator (TMLE)13 to model effect modification for the estimation of the
parameters of the CATE MSM, in the IPD meta-analytical context. In the
supplementary materials, we also describe and evaluate a novel augmented inverse
probability of treatment weighted estimator (A-IPTW). For estimation of the
ATE, TMLE depends on two components: an outcome regression conditional on
treatment and covariates; and, weights comprised of the inverse of the propensity
score where the propensity score is the probability of treatment conditional on
covariates.14 TMLEs are plug in estimators with asymptotic properties that use
a targeting step to optimize the bias-variance trade-off for the target parameter.
In our setting, the estimator we propose allows for differential availability of
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treatments across studies and random effects by study due to measured and
unmeasured characteristics of the study-specific populations.
In Section 2, we describe the MDR-TB data structure and our parameters of
interest. Section 3 introduces the TMLE procedure. We also describe a clustered
influence function-based variance estimator. In Section 4, we present the results of
simulation studies to demonstrate the properties of the estimator under different
scenarios. Then in Section 5, we provide the results based on TMLE analysis of
effect modification for 14 anti-TB medications using the combined IPD of the 31
observational studies.
2 Pooled Observational Studies of MDR-TB
The application data consist of IPD derived from 31 observational studies resulting
in a total of 9290 MDR-TB patients. The data are available to any of the
data contributors, but not publicly available. The systematic review11 extended
three previous systematic reviews.15–17 These IPD were collected from cohorts
of adults with study years ranging from 1995 to 2009. The information collected
for each patient includes demographics (age and sex), past TB history, clinical
characteristics (pre-treatment sputum smear results for acid-fast bacilli (AFB)
and culture, chest radiography, HIV infection), drug susceptibility test (DST)
results, anti-microbial medications given, and outcomes. Our one-stage analytical
approach pools all IPD across studies, accounting for clustering and random
effects.
2.1 Data Structure
2.1.1 Outcome In the pooled dataset, the binary outcome Y represents the
treatment success (the treatment was completed and cured the disease) versus
treatment failure (the patient was still culture positive for MDR-TB, experienced
a relapse or died).18 A patient’s outcome realization is defined as lowercase yij
where (i, j) refers to patient i ∈ Cj in study j and Cj be the set of indices of
patients in study j where j ∈ (1, 2, · · · , J). In the MDR-TB data, there are pooled
data from 31 studies, i.e. J = 31.
2.1.2 Treatments and Treatment Availabilities There are 14 antimicrobial agents
observed in the data: ethambutol (EMB), ethionamide (ETO), ofloxacin
(OFX), pyrazinamide (PZA), kanamycin/amikacin (KM/AM), cycloserine
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(CS), capreomycin (CAP), para-aminosalicylic acid (PAS), prothionamide
(PTO), streptomycin (SM), ciprofloxacin (CIP), later-generation fluoroquinolones
(LgFQ), rifabutin (RIF) and group five level drugs (Gp5). LgFQ included
levofloxacin, moxifloxacin, gatifloxacin and sparfloxacin.11 Gp5 comprised
of amoxicillin-clavulanate, macrolides (azithromycin, roxithromycin, and
clarithromycin), clofazimine, thiacetazone, imipenem, linezolid, high dose
isoniazid, and thioridazine.11 We use k to index the k-th antimicrobial agent,
where k = 1, 2, . . . , 14 in this case. The binary random variable A(k) indicates the
exposure to medication k with patient realizations a
(k)
ij .
Not all treatments are observed in each study; we assume that a given treatment
was available for a given study’s participants based on whether we have observed
that this treatment was taken by any patient in the given study.19 The binary





j = 1 means that the treatment k is available to any
subject i in study j, and is true if at least one patient in this study was prescribed
the treatment k, and otherwise d
(k)
ij = 0.
2.1.3 Baseline Covariates and Resistance Information The baseline covariates
consist of two study level covariates S (the start year of MDR-TB treatment and
the income group of the country of the study) and six individual level covariates
W (age, sex, AFB results, HIV infection, cavitation status on chest radiography
and past TB history).
Resistance information based on DST is defined as the binary variable R(k). In
this dataset, drug resistance information is available for eight medications. Thus,
we denote r(k) = 1 if the patient was found to be resistant to the treatment k and
otherwise r(k) = 0 which includes the situations where the patient’s infection was
susceptible to the treatment or was not known to be resistant to this treatment.
2.1.4 Observed Data Structure The observed data can be written as O =
[S,W , {A(k), D(k), R(k); k = 1, 2, . . . , 14}, Y ]. We will rewrite R = {R(k); k =
1, · · · , 14}, similarly for D and A. Then the data structure is O =
(S,D,W ,R,A, Y ).
2.1.5 Definition of Counterfactual Notation In this data, there is differential
availability of treatments across studies. In order to define a generalized parameter
of interest, we define counterfactual notation under the availability of a given
treatment.19 We define counterfactual exposure to treatment A(k){d(k) = 1} as
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the patient’s counterfactual usage of treatment k had the patient had access. Then
we define the counterfactual outcome Y {d(k) = 1, a(k)} = Y {a(k)} as the patient’s
outcome that would have occurred had treatment k been available and taken.
2.2 Parameter of Interest and Assumptions
As in previous work, we aim to estimate the parameters of interest defined with
respect to a global population which refers to the union of super-populations
specific to each study in this dataset.19,20 We define a non-parametric structural
equation model (NPSEM), which assumes a time ordered data generating
structure, in the Supplementary Materials Appendix A. Then the counterfactual
likelihood is derived under NPSEM and the parameter of interest is defined with
respect to this likelihood.
In this project, for a given medication k, we are interested in estimating the
coefficients of potential effect modifiers V (k) of the effect of medication k in an
MSM for the CATE.7 To define the corresponding parameters, we recall that
patients may take multiple medications concurrently. Given a medication k, we
conduct the analysis by treating all other medications as confounders. For ease of
notation, we define the adjustment set as
X(k) = [S,W ,R, {D(k
∗), A(k
∗); for ∀k∗ ∈ (1, · · · , 14) s.t. k∗ 6= k}]
with realizations x
(k)
ij for individual patients. Here, the symbol asterisk indicates
treatments other than the treatment of interest. The set of potential effect
modifiers investigated is a subset of the adjustment set X(k).7,9 The random
covariate vector is V (k) = {1, V (k)1 , ..., V
(k)
p }. Then we can model the CATE of
treatment k, denoted ψ{V (k)}, as a linear function of potential effect modifiers
such that
E[Y {a(k) = 1} − Y {a(k) = 0}|V (k)] = ψ{V (k);βV (k)} = {V (k)}ᵀβV (k)
where the symbol ᵀ indicates a transpose and βV
(k) = {β(k)0 , β
(k)
1 , ..., β
(k)
p } ∈
Rp+1. The parameter β(k)m ,m 6= 0 represents the difference in the expected causal








Identifying the parameter of interest requires some assumptions that allow us
to write the parameter in terms of distributions of the observed data.19
(a) Consistency: The counterfactual outcome Y {d(k) = 1, a(k) = 1}, where
treatment k was available to and taken by the patient, is the same as the
observed outcome for patients who in fact had access to the treatment and took it.
Additionally, the counterfactual outcome had the patient not taken this treatment
Y {a(k) = 0} is equal to the observed outcome for those who had not taken the
treatment, either due to unavailability or other reasons. In particular, the first
consistency assumption may fail if this treatment was only taken temporarily by
the patient prior to a more effective antimicrobial being substituted in.
(b) Positivity: For the CATE to be estimable without extrapolation, we
also need positivity assumptions. Specifically, the conditional probability of
being treated for each patient given the drug’s availability Pr[A(k){d(k) =
1} = 1|X(k) = x(k), D(k) = 1] and the conditional probability of not being
treated Pr{A(k) = 0|X(k) = x(k)} must both be positive. This may fail if
contraindications exist in the covariates X(k), rendering treatment with A(k)
impossible. Furthermore, Pr{D(k) = 1|S(k) = s(k)}, the probability of availability
of treatment k conditional on the study-level covariates must also be positive.
We also assume that the probability of treatment availability conditional on all
measured covariates is only a function of the study-level covariates. Positivity is
violated when, for example, certain studies occurred in a time or country where
some drugs were not on the market, but only if time or country is a study-level
confounder.
(c) Transportability: The counterfactual outcomes had the patient had access to
the treatment and taken it are independent of treatment availability conditional on
measured covariates, i.e. Y (k){d(k) = 1, a(k) = 1} ⊥ D(k)|X(k). This means that
we can use the measured covariates to fit models where the treatment is available
and use those model fits to estimate overall effects.
(d) In addition, we require unconfoundedness: that the counterfactual outcomes
had the patient taken this treatment be independent of the treatment assignment
conditional on the measured covariates and treatment availability. i.e. Y (k){a(k) =
1} ⊥ A(k)|D,X(k). Moreover, the counterfactual outcomes had the patient not
taken this treatment, Y (k){a(k) = 0}, are independent of the treatment assignment
given the measured covariates.
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Under these assumptions, the CATE can be written as:
ψ{V (k)} =E[E{Y |A(k) = 1,X(k)}|V (k)]− E[E{Y |A(k) = 0,X(k)}|V (k)]
Both right-hand terms can be estimated from the observed data and thus the
CATE is nonparametrically identifiable. A proof is provided in Supplementary
Materials Appendix B.
3 Models and Algorithms
3.1 Outcome and Propensity Score Models
For ease of notation, we will drop the notation k for this section, and consider
A = A(k) for a given k with X = X(k) the adjustment set for k as previously
defined. The doubly robust estimators presented in this section require the
estimation of two quantities, the conditional outcome expectation and propensity
score. We define the former as Q(A,X) = Pr{Y (A = a) = 1|X}, the probability
of counterfactual treatment success conditional on the baseline covariates X. The
propensity score is g(A|X) = Pr(A = a|X), i.e. the conditional probability of
treatment given X.
In our setting with treatment availability variable D and the assumptions listed
in Section 2.2, we note that
Q(1,X) = Pr(Y = 1|A = 1,X) = Pr(Y = 1|D = 1, A = 1,X).
Thus, we can estimate this quantity by fitting a regression model using the
subgroup of subjects who received this treatment, which is necessarily a subset of
those who had access to the treatment. On the other hand, Q(0,X) = Pr(Y =
1|A = 0,X) includes both patients who did not have access to the given treatment
and patients who did but did not receive this treatment.
For the propensity score, the probability of being treated for each patient is:
g(1|X) = Pr(A = 1|D = 1,X)︸ ︷︷ ︸
g1
Pr(D = 1|S)︸ ︷︷ ︸
g2
.
The first component g1 may be estimated by fitting a model using patients who
had access to the treatment. The second part g2 can be obtained by regressing
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treatment availability on study level covariates S. This second regression takes
the study as the unit. Then, we can write the probability of not being treated as
g(0|X) = 1− g(1|X) = 1− g1 · g2.
3.2 Efficient Influence Function
The efficient influence function (EIF) for a specific parameter is the influence
function that achieves the efficiency in the given space of semi-parametric
models.21 The EIF defines the linear approximation of any efficient and regular
asymptotically linear estimator. The EIF for the coefficients βV in a working i.i.d.














with normalizing matrix M = −E( ∂D∂βV ). A proof is provided in Supplementary
Materials Appendix C. An equivalent result was also given by Rosenblum and
van der Laan.22
3.3 TMLE
The general TMLE procedure was proposed by van der Laan and Rubin.23 Our
proposed procedure takes estimates of the conditional expected outcome Q(a,X)
and updates them using information from the propensity score.
The first step is to produce initial estimates for Q(a,X) for a = 1 and 0,
denoted as Qn(1,X) and Qn(0,X), respectively. For each of a = 1 and 0, we
run a weighted logistic regression of Y with offset logit{Qn(a,X)} and covariates
corresponding to the set of potential effect modifiers. The weights are A/gn(1|X)
for a = 1 and (1−A)/gn(0|X) for a = 0, respectively. We then set the updated
Q
∗
n(a,X) equal to the predicted values from the above logistic regression. Finally,




n(0,X) on the potential effect modifiers
in order to obtain the TMLE estimates, β̂V
TMLE
, of the parameters of interest.






V ) = 0.
The estimator thus has the properties of double robustness and local efficiency.
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We also developed a closely related A-IPTW24, which is described in the
Supplementary Materials Appendix D. In finite samples, TMLE has been shown
to perform better than a related A-IPTW if the positivity assumption is nearly
violated or the true values of the parameters of interest are close to the parameter
space boundaries.25
3.4 Influence Function-based Variance Estimator
Standard errors can be estimated for the TMLE using a large-sample sandwich
estimator of the efficient influence function under consistency of Qn(a,X) and
gn(a|X).21 Let βV 0 be the true value of βV and β̂V be the TMLE estimate.
Under regularity conditions, we can write the linear approximation of the
estimator as19
√








where Dij(βV 0) is the influence function at the true values of Q(a,Xij) and
g(a|Xij) for each subject.
In order to estimate the variance of the parameter of interest while taking
clustering by studies into account, we only assume independence between studies,
and not individuals within the same study. Within study j, we denote the
(p+ 1)× (p+ 1) dimension variance-covariance matrix of the efficient influence
function as σ2j . We denote the (p+ 1)× (p+ 1) dimension variance-covariance
matrix of the efficient influence function of any two different subjects in study j
as ρj . Both of these quantities can be estimated from the observed data. Then,
for large J , the variance-covariance matrix of β̂V can be estimated using:
26





















nj(nj − 1)ρj + njσ2j
}]
where nj is the size of study Cj . This variance estimator is only valid for
larger numbers of clusters and consistent estimates of both the outcome and the
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propensity score.19 We investigate its finite-sample performance in the simulation
study. In past work, we have also found that the nonparametric clustered
bootstrap performs well.19,26
4 Simulation Study
We conducted simulation studies in R to develop and evaluate TMLE and
A-IPTW in the implementation to model effect modification for IPD meta-
analysis. We demonstrate the double robustness and finite-sample performance
of TMLE and A-IPTW. Results for the A-IPTW estimator are provided in the
Supplementary Materials Appendix E.
4.1 Data Generation
For each dataset, we generated two continuous study-level covariates, S1 and
S2, where we treated S2 as unobserved. We also generated three individual-
level covariates: W1 continuous and W2 and W3 binary. In this simulation, we
included three treatments where each study had access to one, two or all three.
We denote the treatment availability as D(k), k = 1, 2, 3 which was generated
conditional on the study level covariate S1. Then three treatment indicators A
(k)
were generated based on the values of S1,W1,W2,W3 and D
(k). Subjects could
take any combination of these treatments. Finally, we generated a continuous
outcome Y in a model with and without random effects, conditional on individual-
level covariates, all three treatments, and study-level covariate S1. Specifically,
this model included interactions between the two effect modifiers W1 and W3
and A(1). For random effects by study we added an additional interaction term
between S2 and A
(1). Table S1 in Supplementary Material Appendix E displays
the full data generating mechanism. The observed data structure for each subject
is O = (S1,W1,W2,W3,D,A, Y ).
In this simulation study, we only aimed to estimate the parameters representing
effect modification of treatment k = 1. For both scenarios with the outcomes
involving random effects or not, we drew 1000 simulations with J ∈ {10, 30, 50}
studies where each study contained 300 subjects. This resulted in three total




In order to model the effect modification of treatment k = 1, we included
treatment covariates A(2) and A(3) as confounders, as explained in Section 2.2. We
denote the baseline covariates as X(1) = {S1,W1,W2,W3, A(2), A(3)}. In practice
we are not aware of the true set of effect modifiers so we define the potential set
as {W1,W2,W3, A(2), A(3)} and set V (1) = {1,W1,W2,W3, A(2), A(3)}.
As we discussed in Section 2.2, we model the CATE of treatment A(1) as a






1 W1 + ...+ β
(1)
5 A
(3). Our parameters of interest are thus βV (1) . In the
scenarios without random effects, the true values of these parameters were derived
analytically. For the scenarios with random effects, we generated data with large
sample sizes (106) and forced all A(1) equal to 1 and 0, respectively, to obtain
both counterfactual outcomes. Then we obtained the true values of the parameters
by fitting the linear regression of the differences between the two counterfactual
outcomes on the potential effect modifiers. Given the data generating mechanism
there were two real effect modifiers, W1 and W3. When outcomes were simulated
without random effects, the true corresponding coefficient values were 0.65 and
0.35, respectively. When outcomes were generated with random effects, the true
values were 0.77 and 0.38 (Tables S2, S3 in the Supplementary Materials Appendix
E).
We used logistic regressions to estimate each component of g{A|X(1)},
collectively referred to as g, and Q̄{a,X(1)}, referred to as Q. To control the
potential sources of sparsity, predicted values for g1 and g2 were truncated at
(α, 1− α) where α = 0.001. To demonstrate the double robustness property of
both methods, we ran four different scenarios: 1) correctly specified parametric
models for both Q and g; 2) only the Q model correctly specified and the g model
misspecified as a null model; 3) only the g model correctly specified and the Q
model misspecified as a null model; 4) both Q and g misspecified as null models.
In this simulation, we applied the TMLE algorithms presented in Section
3.3. Note that the TMLE implementation we used requires that we transform
the continuous Y to lie in (0, 1), and then we reverse-transform at the end of
the procedure.27 The standard errors were estimated by the influence function
sandwich estimator, first ignoring clustering and then incorporating clustering
as described in Section 3.4. We compared both standard error estimates to the
Monte Carlo standard errors. Then based on the clustered standard errors, we
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constructed 95% Wald-type confidence intervals and computed the corresponding
coverage rates which are the percentage of times that the confidence intervals
contained the true parameter values.
4.3 Results
Figure 1 presents the results of TMLE for the estimation of five potential effect
modifiers under the four estimation scenarios and three different sample sizes
with outcomes generated without random effects. Figure 2 presents the TMLE
results under random effects. The coverage rates are presented in the blue boxes of
the two figures. More detailed TMLE results are provided in the Supplementary
Materials Appendix E (Tables S2 - S4), along with the figures and tables of the
results of the A-IPTW estimator (Tables S5 - S7 and Figures S1, S2).
From Figures 1 and 2, we see that under the first two scenarios, where the
model for Q was correctly specified, the TMLE estimators had no error on average
regardless of the presence of random effects. Unsurprisingly, under scenario 4 when
all quantities were assigned null models, a small bias was present without random
effects and a larger bias was present with random effects. In scenario 3, where the
model for Q was incorrectly specified but the model for g was correct, the average
error converged to zero as the number of studies increased. The estimates were also
more dispersed than for the previous scenarios. This occurred because the model
for g2 is estimated using the study as the unit in the analysis, so with few studies,
the sample size to fit this model is extremely small. Compared to TMLE, the
A-IPTW estimator had greater average error in scenarios 3 and 4, but otherwise
performed similarly (Table S8 in the Supplementary Materials Appendix E).
The coverage rates, given in the blue boxes of Figures 1 and 2, typically
increased with the number of studies. For instance, with random effects with
10 studies, in scenario 1 where all models were correctly specified, the coverage
rates for the five potential effect modifiers were between 79.8% and 90.1%. With
30 studies, the rates increased to 88.1%− 94.8%. Then for 50 studies, the coverage




81.5% 89.6% 92% 86.6% 94.3% 95.1% 89.3% 96.1% 95% 85.1% 94% 94% 86% 93.5% 95.3%
w1 w2 w3 a2 a3











90.8% 97.6% 97.6% 87.4% 94.5% 94.7% 90.2% 92.7% 92.2% 90.8% 97.3% 96.1% 86.9% 92.6% 94.9%
w1 w2 w3 a2 a3











82.7% 89.8% 91.5% 86.4% 91.7% 95.9% 88.5% 94.3% 95.1% 84.2% 92.2% 93% 84.7% 93.2% 92.6%
w1 w2 w3 a2 a3











93.9% 97.2% 96.1% 89.2% 92% 87.3% 86.4% 85.8% 81.9% 29.4% 11.9% 3.4% 82.4% 90.3% 90.8%
w1 w2 w3 a2 a3











Figure 1. Error of TMLE estimates under four scenarios and three different sample sizes
without random effects. The x-axis represents the number of studies. Coverage rates based
on the clustered sandwich estimators of the standard error are presented in blue boxes. The
four scenarios are as follows: Scenario 1 - both Q and g models are correct; Scenario 2 - Q
model is correct, g is null; Scenario 3 - Q model is null, g model is correct; Scenario 4 -
both Q and g models are null.
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Figure 2. Error of TMLE estimates under four scenarios and three different sample sizes
with random effects. The x-axis represents the number of studies for three sample sizes.
Coverage rates based on the clustered sandwich estimators of the standard error are
presented in blue boxes. The four scenarios are as follows: Scenario 1 - both Q and g
models are correct; Scenario 2 - Q model is correct, g is null; Scenario 3 - Q model is null,
g model is correct; Scenario 4 - both Q and g models are null.
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5 MDR-TB Data Analysis
5.1 Descriptive Statistics of MDR-TB
The combined dataset contained the IPD from 31 observational studies with
a total of 9290 patients. After removing 260 (2.8%) patients without reported
outcomes, 9030 patients taking combinations of 14 different antimicrobial
agents remained. Study-specific sample sizes ranged from 25 to 2182 patients
(Supplementary Materials Appendix F Table S9). Missing values were present in
the covariates; the cavity status variable had the most missing values (25.97%).
Appendix F Table S10 and Figure S3 give summaries of the treatment-specific
sample sizes and the six individual level covariates. Ofloxacin, pyrazinamide and
cycloserine were the three most prescribed medications. In contrast, fewer than
1000 patients were prescribed later-generation fluoroquinolones and ciprofloxacin.
Ethambutol and pyrazinamide were widely prescribed in 30 out of 31 studies,
while only 14 studies had patients who took ciprofloxacin or later-generation
fluoroquinolones. The number of male patients was around twice the number
of female patients in all treatment groups. A total of 4892 (54.33%) patients
were concentrated in the 26− 45 year-old age group while only 154 (1.71%) were
in the 0− 17 year-old group. For the other individual level covariates, about
75% of patients were diagnosed with TB in the past. Moreover, the majority
of patients had cavity (68.33%) and positive AFB (74.53%), but there were only
15% coinfected with HIV.
In order to assess the data support needed to investigate effect modification
by concurrent medication, Table 1 displays the number of patients who used
a combination of any two medications, with the diagonal indicating the total
number of patients taking the corresponding medication. Values ranged between
87 to 4574, indicating at least minimal data support for all pairwise combinations.
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Table 1. Summary of number of patients taking any combinations for any two medications during the treatment period. The diagonal
values represent the total number of patients taking each medication.
EMB CAP CIP CS ETO OFX PAS PTO RIF SM PZA KM/AM LgFQ Gp5
EMB 4188 734 565 1617 2472 2995 989 770 1080 634 3518 2706 272 768
CAP 734 1874 482 1719 900 1328 1386 722 325 151 1119 543 205 923
CIP 565 482 968 782 682 236 616 223 350 232 645 481 127 555
CS 1617 1719 782 5629 1941 4195 3573 3004 523 981 3234 2900 745 1833
ETO 2472 900 682 1941 3911 3175 1206 240 397 309 3433 3014 287 670
OFX 2995 1328 236 4195 3175 6464 2750 2566 465 786 4574 4191 192 1262
PAS 989 1386 616 3573 1206 2750 3937 2292 293 732 1962 1816 644 1463
PTO 770 722 223 3004 240 2566 2292 3304 154 749 1564 1532 449 1065
RIF 1080 325 350 523 397 465 293 154 1261 406 1133 332 87 195
SM 634 151 232 981 309 786 732 749 406 1366 870 192 269 339
PZA 3518 1119 645 3234 3433 4574 1962 1564 1133 870 6102 3775 436 930
KM/AM 2706 543 481 2900 3014 4191 1816 1532 332 192 3775 5015 416 1166
LgFQ 272 205 127 745 287 192 644 449 87 269 436 416 866 511










5.2 Analysis and Results of MDR-TB
For each medication k, the target parameters in this application are the coefficients
of the MSMs,
ψ{V (k);βV (k)} = {V










where V (k) = {1, V (k)1 , · · · , V
(k)
19 } is the set including six individual level covariates
and the 13 medications excluding medication k. We standardized the continuous
variable age. β
(k)
0 represents the baseline effect for the reference group of
female patients with mean age (39), negative AFB test, no cavitation on chest
radiography, no past TB history, no HIV co-infection and not taking any other of
the 13 medications. The associated coefficients β
(k)
j , j = 1, · · · , 19 represent the
difference in the CATE when varying the characteristic V
(k)
j by one unit while
holding other covariates fixed.
As noted, there are missing values in the individual-level covariates. We used
multiple imputation28 by chained equations with the MICE package29 in R to
produce 20 imputations then used Rubin’s rules to combine the estimates.30
In each imputed dataset we followed the procedure described in Section 3.3
to fit a TMLE. We estimated the Q component using SuperLearner (SL)31
which is a methodology that uses cross validation to find an optimal convex
combination of the predictions of a library of candidate algorithms defined by the
user. We included the following algorithms in the SL library: generalized linear
models with penalized maximum likelihood (glmnet function)32,33, with forward
stepwise variable selection (step function), and with a stepwise procedure based
on the Akaike Information Criterion (stepAIC function), respectively.34 Logistic
regressions were used for the g models and LASSO penalties were added when
the logistic regression failed to converge.
In each completed dataset, variance estimates for the coefficients were computed
using the sample variance of the influence function following the expression in
Section 3.4. Finally, since many comparisons made in this analysis, we performed
a multiple testing adjustment of the “significance level” of the p-values to control
the false discovery rate via the method of Benjamini and Hochberg 35 with further
details given in the Supplementary Materials Appendix G.
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Figures 3, 4 and 5 show the estimated coefficients, standard errors and 95%
confidence intervals corresponding to the intercept and six individual-level effect
modifiers and the other 13 medications. The outputs for estimated coefficients
that are statistically significant after adjustment are marked in red color and
with an asterisk. Corresponding tables of the numerical results are also provided
in the Supplementary Materials Appendix F (Tables S11 and S12). From Figure 3
there is no evidence that the six characteristics modify the treatment effect of any
drug. In Figure 4 (CS plot), patients prescribed streptomycin might have benefited
less from cycloserine than patients not receiving streptomycin. In addition, taking
cycloserine was associated with a greater estimated effect of ethionamide while
capreomycin, kanamycin/amikacin drugs were associated with lower estimated
effects (ETO plot).
The empirical distributions of the untruncated propensity scores for all drugs
are provided in the Supplementary Materials Appendix F (Table S13 and Figure
S4). For later-generation fluoroquinolones, we noted very large weights which
likely yielded the large variability observed in Figure 5, LgFQ plot. In addition,
since fewer patients were prescribed later-generation fluoroquinolones among
those who were HIV positive (Appendix F Figure S3), the standard errors were
inflated for the coefficient of HIV in the fluoroquinolones MSM (Figure 3, LgFQ
plot). Also, among those who took rifabutin, only 87/866 subjects were also
prescribed later-generation fluoroquinolones, giving rise to the large standard error
(Figure 5, RIF plot).
To highlight the differences between meta-analysis and individual study results,
we compared the results of Mitnick et al., conducted in 1996-200236,37 for the
effect modification of ethionamide. Given that all 14 medications were observed
in only two studies (Appendix F Table S9), Mitnick et al. (710 subjects) and
Tupasi et al. (170 subjects), we chose Mitnick et. al. to make the comparison.
In Figure 6, we see that a single-study TMLE analysis of the data from the
study by Mitnick et al. concluded that prothionamide was associated with greater
estimated effects of ethionamide while group 5 drugs and rifabutin were associated
with lower estimated effects. Both the meta-analysis and the single study results
agreed that cycloserine and capreomycin were effect modifiers (positive and
negative, respectively). As expected, the estimation in the meta-analysis had
lower standard errors than the individual study (Figure 6). The deviation of the
results suggests heterogeneity between different studies in the meta-analysis. It is
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important to note that analysis of an individual study targets a parameter that
is interpreted in the individual study’s super-population while the meta-analysis
targets the parameter interpreted in the global population. These parameters may
not coincide when there is heterogeneity.
6 Discussion
In this paper, we developed one-stage doubly-robust methods for the analysis
of baseline effect modification in an IPD meta-analysis. The model space that
we considered was nonparametric though the parameters of interest were defined
through a working linear MSM for the CATE. Our approach allowed us to analyze
pooled IPD from multiple studies in order to evaluate how estimated treatment
effects may vary depending on the values of patient covariates. Our past work,
which proposed related methods and a TMLE for IPD meta-analysis with multiple
treatments, instead estimated a treatment importance metric defined as the
difference in adjusted probabilities of treatment success between the patients who
used each medication and the overall population.19 Our current work proposes
a novel TMLE and A-IPTW for the estimation of effect modification in the
described marginal structural model in an IPD meta-analysis.
Vo et al. illustrated that in IPD meta-analysis, heterogeneity across studies
can come from two sources: case-mix heterogeneity, due to effect modification,
and beyond case-mix heterogeneity, due to differences in study design and
measurement.38 Our methods address heterogeneity by allowing for differential
availability of treatments across studies and random effects by study due to
measured and unmeasured characteristics of the study-specific populations.
In clinical and epidemiological research, model misspecification is always
a concern when estimating treatment or exposure effects. Doubly robust
methods yield consistent estimators even under misspecification of either the
treatment or the outcome model. In the simulation study, we demonstrated the
double robustness property of both TMLE and A-IPTW. We observed similar
performance of TMLE and A-IPTW but we did not investigate near-positivity
violations or other scenarios that may differentiate them in finite samples as
have others.25,39 In addition, we demonstrated the double robustness of both
methods when there are study-specific random effects for the outcome. Finally,
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Group 5 drugs (Gp5)
Figure 3. Estimated coefficients and the corresponding 95% confidence interval for 14
medications relative to the intercept and six demographic or clinical covariates. None of the
coefficients reached statistical significance.












































































































































































































Figure 4. Estimated coefficients of potential effect modifiers and the corresponding 95%
confidence intervals for EMB, CAP, CIP, CS, ETO and OFX. Significant results are shown









































































































































































































































































































Group 5 drugs (Gp5)
Figure 5. Estimated coefficients of potential effect modifiers and the corresponding 95%
confidence intervals for PAS, PTO, RIF, SM, PZA, KM/AM, LgFQ and Gp5. None of the
coefficients reached statistical significance.
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Ethionamide (ETO) in meta−analysis
Figure 6. Estimated coefficients of potential effect modifiers and the corresponding 95%
confidence intervals for ETO in the study by Mitnick et al. (left column) and in the
meta-analysis (right column). Significant results are shown in red and indicated with an ∗.
function sandwich estimator that considers clustering by study, performed well
when there were greater than 30 studies in the analysis. Indeed, a limitation
of our approach is that it relies on a sufficient number of studies to estimate
the generalized parameter interpreted in the global population. In particular, the
ability to adjust for confounding by treatment availability depends on fitting a
model for treatment availability conditional on study-level covariates, which is
limited by the typically small number of studies in a meta-analysis. Indeed, we
observe in the simulation study that error may persist when the number of studies
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is small and the outcome regression model is incorrectly specified, even when
the propensity score model components are correctly specified with parametric
models. Therefore, our approach should only be undertaken when a larger number
of studies are available.
The treatment of MDR-TB is challenging because of its prolonged duration,
toxicity, costs and unsatisfactory outcomes.1 Second-line TB medicines used
for the treatment of drug-resistant TB include injectable drugs (capreomycin,
streptomycin, kanamycin or amikacin), fluoroquinolones (ciprofloxacin, ofloxacin
or later-generation fluoroquinolones), ethionamide or prothionamide, para-
aminosalicyclic acid and cycloserine. The WHO (2019) revised the guidelines and
currently suggest that streptomycin and amikacin are to be considered only if
DST results confirm susceptibility and adequate measures to monitor for adverse
reactions can be ensured. In addition, capreomycin and kanamycin are not to
be included in the treatment of MDR-TB patients.4 Currently, in general, the
selection of antimicrobials for the treatment of an individual patient with TB
is based, apart from drug availability, on issues such as the mycobacteria’s drug-
resistance pattern and assumptions about the chosen drugs (mechanism of action,
potential toxicity, known pharmacological interactions, possible development of
drug resistance due to previous use, etc.). However, the actual role played by each
drug in the therapeutic outcome is difficult to assess because of the large number
of possible combinations of antimicrobials and the potential yet undiscovered
interactions affecting their pharmacokinetic and/or pharmacodynamic properties.
The statistical approach proposed by the present study takes advantage of the
IPD meta-analysis in order to unveil treatment effect modifiers, either regarding
medications or other variables at the individual-level, with the aim to better treat
and understand not only TB, but also other diseases, including those requiring
the concurrent use of several drugs such as arterial hypertension, diabetes, etc.
As discussed in Section 2.2, we require unconfoundedness when estimating
the causal effect. However, in practice, this condition is non-testable and we are
limited to the covariates collected by the original studies. While most important
confounders were collected across all studies, we did not receive DST results from
many studies. However, the results were available to clinicians who may have
responsively changed or added medications, making DST results an important
confounder. Our analyses adjusted for all available drug sensitivity information.
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Our results suggest that cycloserine may enhance the effects of ethionamide but
capreomycin and kanamycin or amikacin were associated with reduced effects.
In addition, streptomycin may reduce the effect of cycloserine. Our findings
support the revised WHO guidelines that injectable drugs are not as beneficial as
previously believed. The analyses informing the 2019 WHO guidelines (Ahmad
et al.) showed that kanamycin and capreomycin were associated with worse
outcomes.40 In our results, these drugs were associated with worse outcomes in
regimes with ethionamide. For the six individual characteristics, age, sex, acid
fast bacilli status, HIV infection, cavitation status on chest radiography, and past
TB history, they might be potential for effect modifiers since we did not find
any evidence of effect modification. Being that MDR-TB an infectious disease,
this finding may simply reflect that antimicrobial drugs play a much larger and
definitive role for success than other characteristics at the individual level.
Since our MDR-TB data were identified from studies carried out up to
2009, we have no information about both new and repurposed effective anti-TB
drugs.41,42 Upcoming work will apply our methods to data from more recently
treated patients. Another limitation of our approach is that, because we only
considered the effect of intervening on one treatment at a time, we cannot directly
address how to select combinations of medications that would be expected to
optimize the probability of treatment success. Previous work evaluated the causal
contrasts between different regimens of concurrent medications in MDR-TB.43
Future applications should directly address the more challenging question of
treatment-treatment interactions on the outcome which would directly allow for
the evaluation of optimal medication usage. Other ongoing work in our group
involves using LASSO,33 rather than hypothesis testing, to select the effect
modifiers in the linear MSM for the CATE. This may improve upon the current
work by utilizing a superior approach to variable selection.
Identifying effect modifiers is an important step for estimating subpopulation
causal effects that can help guide treatment decision making for individual
patients. However, such analyses require larger amounts of data than the
estimation of average treatment effects. This analytic approach can generate
hypotheses for drug combinations which can be tested in randomized controlled
trials. We have also contributed by extending existing doubly robust methods
to incorporate multiple data sources. Advances in IPD meta-analysis enable
researchers to incorporate multiple sources of previously collected observational
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data in their analyses in order to increase their power, which is greatly beneficial
for the identification of effect modifiers.
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